-
'Would You Open Source The Manhattan Project': Vinod Khosla And Marc Andreessen Clash Over Musk's OpenAI Lawsuit
Monday, March 4, 2024 - 5:17am | 796Read More...Venture capitalists Vinod Khosla and Marc Andreessen have slammed each other over tech billionaire Elon Musk's lawsuit against OpenAI and Sam Altman. What Happened: Khosla, an early OpenAI investor, questioned Andreessen over his stance on open-sourcing critical technologies like artificial...
-
OpenAI Investor Vinod Khosla Ponders About This 'Key Question' As Billionaires Start Wondering About Interest Rate Cuts
Wednesday, December 27, 2023 - 8:35am | 651Read More...OpenAI investor Vinod Khosla thinks that while artificial intelligence (AI) will have a major impact on the global economy, the key question is how economic health will be measured in such an environment. What Happened: Khosla's comments come at a time when billionaires – including OpenAI CEO Sam...
-
OpenAI Investor Vinod Khosla Works 80 Hours A Week, Will Use Peter Thiel's Anti-Aging Methods If They Work
Friday, December 1, 2023 - 10:27pm | 646Read More...OpenAI investor and Sun Microsystems co-founder Vinod Khosla said that even at 68, he works 80 hours a week and intends to do so for the next 25 years. What Happened: Khosla said he would even try and extend his life using Peter Thiel's anti-aging methods if they work, just so he can continue to...
-
Microsoft, Investors Stand Solidly Behind 'Once In A Generation' CEO Sam Altman, Putting OpenAI Board Under Pressure
Sunday, November 19, 2023 - 11:41am | 910Read More...The OpenAI saga continued to play out over the weekend with a lot of twists and turns. Former CEO Sam Altman and fellow co-founder Greg Brockman reportedly received a lot of support from big investors and employees following their exit, increasing their chances of being reinstated. Microsoft,...
-
Editas Medicine, Backed By Google And Bill Gates, Files $100 Million IPO
Tuesday, January 5, 2016 - 4:19pm | 299Read More...Editas Medicine, a Cambridge, Massachusetts-based drugmaker backed by Bill Gates and Google Ventures among others, filed its initial public offering paperwork on Monday. The company specializes in a new gene-editing technique called Crispr, and will become the first publicly traded firm to focus...
